Neoleukin Therapeutics (Neoleukin Therapeutics) Scaled Net Operating Assets : 0.08 (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neoleukin Therapeutics's operating assets for the quarter that ended in Sep. 2023 was $11.08 Mil. Neoleukin Therapeutics's operating liabilities for the quarter that ended in Sep. 2023 was $3.66 Mil. Neoleukin Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $94.01 Mil. Therefore, Neoleukin Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was 0.08.

Neoleukin Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Neoleukin Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Scaled Net Operating Assets Chart

Neoleukin Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.04

0.07

0.06

Neoleukin Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.08	0.08	0.08	0.09	0.08

Competitive Comparison of Neoleukin Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Neoleukin Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neoleukin Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's Scaled Net Operating Assets falls into.

Neoleukin Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Neoleukin Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(19.564	-	9.547)	/	163.263
=	0.06

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	115.948	-	96.384
=	19.564

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	21.617	-	10.555	-	1.515
=	9.547

Neoleukin Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2023 )
=	(Operating Assets (Q: Sep. 2023 )	-	Operating Liabilities (Q: Sep. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(11.079	-	3.658)	/	94.005
=	0.08

where

	Operating Assets		(Q: Sep. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	89.586	-	78.507
=	11.079

	Operating Liabilities		(Q: Sep. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	14.351	-	9.139	-	1.554
=	3.658

Neoleukin Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102

Website

https://www.neoleukin.com

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Executives

Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith	officer: Principal Accounting Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel	officer: Chief Medical Officer	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle	director	C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener	officer: General Counsel, SVP Legal	C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar	director	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman	director, officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey	officer: Senior Vice President	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho	officer: Chief Financial Officer	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance	officer: General Counsel	C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle	director	360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080